Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study

Mysler, Eduardo; Spindler, Alberto; Guzmán, Renato; Bijl, Marc; Jayne, David; Furie, Richard; Houssiau, Frédéric; Drappa, Jörn; Close, D.; Maciuca, Romeo; Rao, Kajal; Shahdad, Saba; Brunetta, Paul

doi:10.1002/art.38037

Public

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study

Published in Arthritis & Rheumatism • Jun 5, 2013

Authors:

Eduardo Mysler

Alberto Spindler

Renato Guzmán

Abstract

OBJECTIVE: To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). METHODS: Patients were randomized 1:1:1 to receive placebo, 400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an intravenous infusion on days 1 and 15, followed by a single infusio...

Subject

Ocrelizumab

Medicine

Lupus nephritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!